We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up
Read MoreHide Full Article
Geron Corporation (GERN - Free Report) reported a loss of 5 cents per share for the fourth quarter of 2017, which was wider than the Zacks Consensus Estimate of a loss of 4 cents and flat with the year-ago period.
Quarterly revenues surged 103% to $0.19 million from the year-ago quarter. Revenues, however, missed the Zacks Consensus Estimate of $1 million. Revenues comprised royalty and license fee revenues received under various non-imetelstat license agreements.
Shares were up 7.4% in after-hours trading on Mar 16. Moreover, so far this year, Geron’s shares have outperformed the industry, rising 87.2% during the period compared with the industry’s gain of 1.4%.
Research and development (R&D) expenses declined 39% to $2.5 million due to lower costs for the proportionate share of clinical development costs for imetelstat. General and administrative (G&A) expenses rose 14.6% to $5.5 million due to increased stock-based compensation and consulting costs, partially offset by lower legal costs.
The company ended the quarter with $109.2 million in cash and investments compared with $112.7 million at the end of the third quarter.
2017 Results
Revenues for the full year were significantly down to $1.1 million from $6.2 million in the year-ago period. We note that revenues in the year-ago quarter had included a $5 million upfront payment from Johnson & Johnson’s (JNJ - Free Report) subsidiary Janssen related to a licensing agreement.
The company reported a loss of 18 cents for the year, narrower than year-ago loss of 19 cents.
R&D expenses were down 38.9% to $11 million while G&A expenses were up 2.7% to $19.3 million.
Pipeline Update
Geron’s sole pipeline candidate, imetelstat, is being evaluated in two mid-stage studies – IMerge and IMbark – in myelodysplastic syndromes (“MDS”) and myelofibrosis (“MF”), respectively. Geron is conducting the studies in collaboration with J&J.
In December 2017, Geron presented preliminary data from part I of phase II/III IMerge study. Data showed that imetelstat achieved RBC transfusion-independence (RBC-TI – reduced or no requirement of RBC transfusion over a certain interval) in 54% of the patient population, who have not received prior treatment with either lenalidomide or a hypomethylating agent, for at least 8 weeks. RBC-TI was achieved in 31% of the patients in the above subset for at least 24 weeks.
Based on this data, J&J expanded part I of the study to include 20 more patients in refined MDS indication to confirm the clinical benefit and safety observed earlier. In October 2017, the FDA granted fast track designation to imetelstat based on data from part 1 of IMerge.
Meanwhile, the clinical benefit and a potential overall survival benefit observed during the third internal review in March 2018 supported continuation of the phase II IMbark study without modifications.
However, J&J is planning to amend the protocol of the study to allow long-term treatment of patients. The amendment will be based on a primary analysis of data from the study, which is expected in the second quarter of 2018. J&J will also notify Geron about continuation of the study based on this analysis, which is expected in the third quarter of 2018.
Geron Corporation Price, Consensus and EPS Surprise
Horizon Pharma’s earnings estimates increased 10% to $1.43 for 2018 and 15% to $1.77 for 2019 over the last 30 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 68.92%.
Ligand’s earnings per share estimates increased 11% to $4.20 for 2018 and 12% to $5.32 for 2019 over the last 30 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 24.88%. The company’s shares are up 25.5% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Geron (GERN) Q4 Loss Flat Y/Y, Revenues Surge, Shares Up
Geron Corporation (GERN - Free Report) reported a loss of 5 cents per share for the fourth quarter of 2017, which was wider than the Zacks Consensus Estimate of a loss of 4 cents and flat with the year-ago period.
Quarterly revenues surged 103% to $0.19 million from the year-ago quarter. Revenues, however, missed the Zacks Consensus Estimate of $1 million. Revenues comprised royalty and license fee revenues received under various non-imetelstat license agreements.
Shares were up 7.4% in after-hours trading on Mar 16. Moreover, so far this year, Geron’s shares have outperformed the industry, rising 87.2% during the period compared with the industry’s gain of 1.4%.
Research and development (R&D) expenses declined 39% to $2.5 million due to lower costs for the proportionate share of clinical development costs for imetelstat. General and administrative (G&A) expenses rose 14.6% to $5.5 million due to increased stock-based compensation and consulting costs, partially offset by lower legal costs.
The company ended the quarter with $109.2 million in cash and investments compared with $112.7 million at the end of the third quarter.
2017 Results
Revenues for the full year were significantly down to $1.1 million from $6.2 million in the year-ago period. We note that revenues in the year-ago quarter had included a $5 million upfront payment from Johnson & Johnson’s (JNJ - Free Report) subsidiary Janssen related to a licensing agreement.
The company reported a loss of 18 cents for the year, narrower than year-ago loss of 19 cents.
R&D expenses were down 38.9% to $11 million while G&A expenses were up 2.7% to $19.3 million.
Pipeline Update
Geron’s sole pipeline candidate, imetelstat, is being evaluated in two mid-stage studies – IMerge and IMbark – in myelodysplastic syndromes (“MDS”) and myelofibrosis (“MF”), respectively. Geron is conducting the studies in collaboration with J&J.
In December 2017, Geron presented preliminary data from part I of phase II/III IMerge study. Data showed that imetelstat achieved RBC transfusion-independence (RBC-TI – reduced or no requirement of RBC transfusion over a certain interval) in 54% of the patient population, who have not received prior treatment with either lenalidomide or a hypomethylating agent, for at least 8 weeks. RBC-TI was achieved in 31% of the patients in the above subset for at least 24 weeks.
Based on this data, J&J expanded part I of the study to include 20 more patients in refined MDS indication to confirm the clinical benefit and safety observed earlier. In October 2017, the FDA granted fast track designation to imetelstat based on data from part 1 of IMerge.
Meanwhile, the clinical benefit and a potential overall survival benefit observed during the third internal review in March 2018 supported continuation of the phase II IMbark study without modifications.
However, J&J is planning to amend the protocol of the study to allow long-term treatment of patients. The amendment will be based on a primary analysis of data from the study, which is expected in the second quarter of 2018. J&J will also notify Geron about continuation of the study based on this analysis, which is expected in the third quarter of 2018.
Geron Corporation Price, Consensus and EPS Surprise
Geron Corporation Price, Consensus and EPS Surprise | Geron Corporation Quote
Zacks Rank & Stocks to Consider
Geron currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the pharma sector include Horizon Pharma Public Limited Company and Ligand Pharmaceuticals Incorporated (LGND - Free Report) . Both the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Horizon Pharma’s earnings estimates increased 10% to $1.43 for 2018 and 15% to $1.77 for 2019 over the last 30 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 68.92%.
Ligand’s earnings per share estimates increased 11% to $4.20 for 2018 and 12% to $5.32 for 2019 over the last 30 days. The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 24.88%. The company’s shares are up 25.5% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>